Acepodia Inc. (hereinafter referred to as Acepodia), was co-founded by Dr. Patrick Y. Yang and Dr. Sonny Hsiao in February 2017. Dr. Yang, the Chairman of the company, has held key positions such as Global Head of Technical Operations at Roche, Vice President and Deputy General Manager at Genentech, and Merck & Co. He possesses decades of multinational pharmaceutical management experience. Dr. Sonny Hsiao, the CEO, is a young entrepreneur and the inventor of the company’s core technology, Antibody-Cell Conjugation (ACC). This technology is derived from the Nobel Prize-winning research in the field of click chemistry by Professor Carolyn Bertozzi at Stanford University. Acepodia also has a seasoned industry expert, Dr. Harry Lam, a Biologics Manufacturing expert who worked at Genentech, Inc. and Sanofi S.A., serving as the Chief Technology Officer.
Acepodia focuses on developing next-generation cell-based immunotherapies for unmet medical needs in solid tumors and hematologic cancers. By leveraging the ACC technology platform and combining it with its proprietary intellectual property, Acepodia has developed a series of antibody-conjugated effector cell (ACE) therapeutic products using δγ2T cells and oNK cells. These products are designed as “allogeneic” and “off-the-shelf” cell therapy products. Acepodia’s most advanced cell therapy candidates are ACE1831 (δγ2T cells conjugated with CD20 antibody for the treatment of hematologic tumors) and ACE1702 (oNK cells conjugated with HER2 antibody for the treatment of solid tumors). Both candidates have received IND approval from regulatory authorities in Taiwan and the United States to proceed with Phase I clinical trials.
|2017||Acepodia was founded in the United States and Taiwan.|
|2018||Acepodia completed USD 10 million in Series A fundraising|
|2020||Acepodia received US FDA clearance of IND for ACE1702’s Phase 1 clinical study.|
|2020||Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies.|
|2021||Acepodia completed USD 47 million in Series B fundraising.|
|2021||Acepodia received TFDA approval of IND for ACE1702’s phase1 clinical study.|
|2021||Acepodia Presents Positive Interim Phase 1 Feasibility Data of ACE1702, demonstrating safety and tolerability of repeat dosing, in Advanced HER2-Positive Tumors at 2021 EMSO Virtual Congress.|
|2021||Acepodia completed USD 109 million in Series C fundraising.|
|2022||Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting.|
|2022||Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin’s Lymphoma|
|2022||Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting|
|2023||Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors|
|2023||Acepodia received TFDA approval of IND for ACE183’s phase1 clinical study.|
|2023||Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform|